Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard prepares to Ring in New Year

This article was originally published in The Gray Sheet

Executive Summary

Group President Timothy Ring is expected to succeed William Longfield as CEO in 2003. Ring, 45, has a background in personnel management. He joined the company in 1992 as VP-human resources after a 10-year career with Abbott, where he ultimately rose to director of personnel in the Hospital Products division. Ring was promoted to Bard group VP in 1993 and assumed his current responsibilities in 1997. Longfield, who announced plans to retire during this year's aborted merger with Tyco, is expected to stay on as chairman until he turns 65 in August. Bard maintains, however, that the selection process may not be completed until the spring of 2003...

You may also be interested in...

Bard succession plan

Group President Timothy Ring's accession to chairman and CEO, effective upon William Longfield's retirement Aug. 7, is confirmed by the company Feb. 13. The move was anticipated last fall although the firm had insisted the choice was not yet final (1"The Gray Sheet" Oct. 21, 2002, In Brief). Ring, 45, joined the firm in 1992 as VP-human resources, became group VP-international in 1993, and assumed his current responsibilities in 1997, most recently supervising the firm's Vascular and Specialty Access businesses. Bard Group President John Weiland, 47, will become president and chief operating officer in August under the succession plan...

EWG Study Suggests More Than One In 10 Talc-Based Cosmetics Contain Asbestos

The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts